The CHARM-Preserved trial recruited 3023 patients with heart failure but no evidence of left ventricular dysfunction. Patients were randomised to treatment with candesartan or placebo.
There was no reduction in the primary outcome of the trial however there was a small reduction in admissions to hospital with heart failure.
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. (2003). Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386):777-81.
Last reviewed 01/2018